Welcome to our dedicated page for Biostax news (Ticker: BTAX), a resource for investors and traders seeking the latest updates and insights on Biostax stock.
The Biostax Corp (BTAX) news page on Stock Titan provides a focused view of company announcements and developments for this biopharmaceutical issuer. Biostax describes itself as a hub-and-spoke biotech development engine that acquires and develops immune restoration pharmaceutical and MedTech products, with an emphasis on autoimmune, inflammatory, and infectious diseases.
News related to Biostax includes disclosures about its corporate evolution, such as the approval of its name change from Immune Therapeutics, Inc. to Biostax and the transition to trading on the OTC Pink Markets under the ticker BTAX. Company communications have also highlighted a strategic pivot toward international commercial application of substance abuse solutions and a continued commitment to advancing HIV treatment.
Investors and observers can expect Biostax news items to cover topics such as pipeline updates, including information on the JKB-122 drug candidate and its FDA-authorized clinical trials in autoimmune hepatitis, NASH, and NAFLD, as well as planned development in HIV adjunct therapy. Additional news has addressed participation in initiatives like the U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day events, reflecting the company’s interest in collaborative efforts against HIV.
Biostax has also issued announcements about changes in its Board of Directors and about its plan to voluntarily delist its common stock from the OTC Pink marketplace and deregister under the Securities Exchange Act of 1934. For users tracking BTAX, this news feed offers a centralized place to review these corporate, clinical, and strategic updates over time.
Biostax Corp (BIOX) has announced its decision to voluntarily delist from the OTC Pink marketplace and deregister from the SEC, following 76.4% shareholder approval through a Joint Written Consent. The company plans to file Form 25 with the SEC on March 15, 2025, with delisting becoming effective ten days later.
The company will simultaneously file Form 15 to deregister its common stock under the Securities Exchange Act of 1934. Management believes the current public market valuation doesn't reflect their achievements and potential, and operating as a private company will provide greater flexibility and reduce administrative costs.
Biostax's pipeline includes JKB-122, which has received FDA authorization for clinical trials in Autoimmune Hepatitis for newly diagnosed patients and Phase 2 trials for NASH and NAFLD. The company also plans an IND filing for JKB-122 as an adjunct therapy in HIV treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.